The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade
Open accessAbstract
BACKGROUND: Application of curative therapy for hepatocellular carcinoma is crucially dependent on underlying liver function. Using the recently described ALBI grade we examined the long-term impact of liver dysfunction on survival of early-stage hepatocellular carcinoma (HCC) patients. METHODS: This cohort study comprised 2559 HCC patients from different geographic regions, all treated with curative intent. We also examined the relation between indocyanine green (ICG) clearance and ALBI score. Survival was measured from the date of treatment to the date of death or last follow-up. RESULTS: The ALBI score correlated well with ICG clearance. Among those undergoing surgical resection, patients with ALBI grade-1 (good liver function) survived approximately twice as long as those with ALBI grade-2 (less good liver function), although more than 90% of these patients were classified as Child-Pugh (C-P) grade A. In the cohort receiving ablative therapies, there was a similar difference in survival between ALBI grade-1 and grade-2. Cox regression analysis confirmed that the ALBI score along with age, gender, aetiology and tumour factors (AFP, tumour size/number and vascular invasion) independently influenced survival in HCC patients receiving curative treatments. CONCLUSIONS: The ALBI score represents a simple approach to the assessment of liver function in patients with HCC. After potentially curative therapy, those with ALBI grade-1 survived approximately twice as long as those with ALBI grade-2. These data suggest that ALBI grade-1 patients are appropriately treated with surgical resection whereas ALBI grade-2 patients may, where the option exists, be more suitable for liver transplantation or the less invasive curative ablative therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Cited by
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Self-citationChan, A. W. H., Zhong, J., Berhane, S., Toyoda, H., Cucchetti, A., Shi, K., Tada, T., Chong, C. C. N., Xiang, B.-D., Li, L.-Q., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.08.027 · Cited by 546
Self-citation
Metadata
- Authors
- Toyoda, H., Lai, P. B., O'Beirne, J., Chong, C. C., Berhane, S., Reeves, H., Manas, D., Fox, R. P., Yeo, W., Mo, F., Chan, A. W., Tada, T., Iñarrairaegui, M., Vogel, A., Schweitzer, N., Chan, S. L., Sangro, B., Kumada, T., & Johnson, P. J.
- Venue
- British Journal of Cancer
- Published
- 2016-03
- Volume
- 114
- Issue
- 7
- Pages
- 744-750
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2328641557
- Cited by
- 176
- References
- 1
- FWCI
- 15.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. https://app.cochat.ai/papers/10.1038/bjc.2016.33
- The paper
- Toyoda, H., Lai, P. B., O'Beirne, J., Chong, C. C., Berhane, S., Reeves, H., Manas, D., Fox, R. P., Yeo, W., Mo, F., Chan, A. W., Tada, T., Iñarrairaegui, M., Vogel, A., Schweitzer, N., Chan, S. L., Sangro, B., Kumada, T., & Johnson, P. J. (2016). Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. British Journal of Cancer. https://doi.org/10.1038/bjc.2016.33
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.